The top 10 public biotechnology companies in terms of revenue generation posted combined sales of $93.01 billion last year (2012), a growth of 12.1% on 2011. The list below shows that one biotechnology company posted sales accounting for a third of that revenue (Source: PharmaLive):
|Rank (2012)||Company||Revenue in 2012||Net Income in 2012|
(biotech sales estimate)
(for entire Roche Group)
|3||Gilead Sciences Inc.||$9,702,517,000||2,591,566,000|
|4||Biogen Idec Inc.||$5,516,461,000||1,380,033,000|
|10||Novo Nordisk A/S||$2,958,979,317
(biopharma sales only)
The figures come from the 22nd Annual Report: Top 100 Biotechnology Companies, available on PharmaLive.
Roche's fortunes might be set to continue, with industry analysts estimating global sales of Roche's new HER2-positive breast cancer drug Perjeta to reach nearly $2 billion during 2016, and the company's new antibody-drug conjugate Kadcyla also looking to bring in significant revenue.
You've read the Top 10 Biotech Earners, but what about the Top 10 Biotech R&D Spenders of 2012?
YOU MIGHT BE INTERESTED IN: Top 50 Pharmaceutical Companies by R&D Investment Worldwide in 2011
What do you think of this list? Are there any surprises? Why not join our discussion on LinkedIn, or leave a comment below. Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.